Natural Biocon (India) Analysis

dividend

Pros

Cons

• Unable to evaluate Natural Biocon (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Natural Biocon (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Natural Biocon (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Natural Biocon (India) has been profitable on average in the past, therefore cash runway is not a concern.
• Natural Biocon (India) has been profitable on average in the past, therefore cash runway is not a concern.
• Debt is covered by short term assets, assets are 1.6x debt.
• Natural Biocon (India)'s cash and other short term assets cover its long term commitments.
• Natural Biocon (India)'s level of debt (6.5%) compared to net worth is satisfactory (less than 40%).

Cons

• Operating cash flow is negative therefore debt is not well covered.
• High level of physical assets or inventory.

management

Pros

Cons

• The average tenure for the Natural Biocon (India) board of directors is less than 3 years, this suggests a new board.

misc

Pros

Cons

• Natural Biocon (India) is not covered by any analysts.
• Natural Biocon (India)'s last earnings update was 238 days ago.

past

Pros

Cons

• Unable to compare Natural Biocon (India)'s 1-year earnings growth to the 5-year average as it is not currently profitable.
• Natural Biocon (India) does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
• It is difficult to establish if Natural Biocon (India) has efficiently used its assets last year compared to the IN Market industry average (Return on Assets) as it is loss-making.
• It is difficult to establish if Natural Biocon (India) improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
• It is difficult to establish if Natural Biocon (India) has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
• Unable to compare Natural Biocon (India)'s 1-year growth to the IN Market industry average as it is not currently profitable.

value

Pros

Cons

• Natural Biocon (India) is overvalued based on assets compared to the IN Market industry average.
• Natural Biocon (India) is overvalued based on earnings compared to the IN Market industry average.
• Natural Biocon (India) is overvalued based on earnings compared to the India market.